CLAIMS

1. Use of a soluble Fibroblast Growth Factor Receptor 1 (FGFR 1) fusion protein in the manufacture of a medicament for the treatment of cancer in a human; wherein the fusion protein comprises an extracellular domain of an FGFR 1 polypeptide linked to a fusion partner; wherein the human has a fibroblast growth factor-2 (FGF-2) plasma concentration of at least 6 pg/ml, wherein the fusion protein is to be administered at a dose of at least about 2 mg/kg body weight~~; and wherein~~ such that the FGFR1 fusion protein reduces the free FGF-2 plasma concentration of the human ~~below~~ to less than 4 pg/ml ~~for at least one week~~at seven days after administration.

2. Use of a soluble Fibroblast Growth Factor Receptor 1 (FGFR 1) fusion protein in the manufacture of a medicament for the treatment of cancer in a human; wherein the fusion protein comprises an extracellular domain of an FGFR1 polypeptide linked to a fusion partner; wherein the cancer is characterized by a Fibroblast Growth Factor Receptor 2 (FGFR2) having a ligand-dependent activating mutation, wherein the fusion protein is to be administered at a dose of at least about 2 mg/kg body weight~~; and wherein~~ such that the FGFR1 fusion protein reduces ~~a~~ the free FGF-2 plasma concentration of the human ~~below~~ to less than 4 pg/ml ~~for at least one week~~at seven days after administration.

3. The use according to claim 1 or 2, wherein the fusion partner is Fc polypeptide.

4. The use according to claim 1, 2 or 3, wherein the FGFR1 extracellular domain comprises the amino acid sequence of SEQ ID NO: 5.

5. The use according to any one of the preceding claims, wherein the soluble FGFR1 fusion protein comprises the amino acid sequence of SEQ ID NO: 8.

6. The use according to any one of the preceding claims, wherein the soluble FGFR1 fusion protein is to be administered at a dose of about 2 mg/kg body weight to about 20 mg/kg body weight, such as a dose of about 8 mg/kg body weight to about 16 mg/kg body weight.

7. The use according to claim 6, wherein the soluble FGFR1 fusion protein is to be administered at a dose of about 8 mg/kg body weight.

8. The use according to claim 6, wherein the soluble FGFR1 fusion protein is to be administered at a dose of about 16 mg/kg body weight.

9. The use according to any one of the preceding claims, wherein the cancer is prostate cancer, breast cancer, colorectal cancer, lung cancer, endometrial cancer, head and neck cancer, laryngeal cancer, liver cancer, renal cancer, glioblastoma, or pancreatic cancer.